CommercialCoverageMedium impact
08.01.98d, Teclistamab-cqyv (Tecvayli®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
May 4, 2026
We identified it
Jun 19, 2026
Summary
This policy updates medical necessity criteria and coding requirements for Teclistamab-cqyv (Tecvayli®), a medication used for treating multiple myeloma. The changes affect both coverage determination processes and billing code usage for this specialty oncology drug.
Action Required
Before May 4, 2026: Oncology billing team must review and update medical necessity documentation requirements for Teclistamab-cqyv (Tecvayli®) claims. Update billing system with new coding guidelines and ensure prior authorization processes align with updated criteria. Verify current billing codes are still valid under new policy.